Holen Sie sich die Stockscreener-App
19.83
1.05%
-0.21
Handel nachbörslich:
19.83
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
Jane Street Group LLC Has $3.54 Million Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
State Street Corp Sells 337,262 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia - The Manila Times
Nurix Therapeutics Receives U.S. FDA Fast Track Designation - GlobeNewswire
Nurix's BTK Degrader NX-5948 Earns FDA Fast Track Status for Rare Blood Cancer Treatment - StockTitan
State Street Corp Cuts Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics' SWOT analysis: btk degrader stock shows promise amid challenges - Investing.com
Lord Abbett & CO. LLC Purchases Shares of 350,640 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Target Price at $30.35 - MarketBeat
When (NRIX) Moves Investors should Listen - Stock Traders Daily
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stake Boosted by The Manufacturers Life Insurance Company - Defense World
BTIG Initiates Coverage of Nurix Therapeutics (NRIX) with Buy Recommendation - MSN
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Acquired by Fmr LLC - MarketBeat
Is Nurix Therapeutics (NRIX) the Worst ARK Stock to Buy According to Short Sellers? - MSN
Nurix Therapeutics (NASDAQ:NRIX) Given New $35.00 Price Target at HC Wainwright - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Purchased by Wellington Management Group LLP - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Coverage Initiated at BTIG Research - MarketBeat
Nurix Therapeutics' (NRIX) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Nurix Therapeutics Reports Promising Trial Results for NX-5948 - TipRanks
Nurix Therapeutics's SWOT analysis: btk degrader stock shows promise amid challenges By Investing.com - Investing.com South Africa
Nurix Therapeutics's SWOT analysis: btk degrader stock shows promise amid challenges - Investing.com India
Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting - The Manila Times
Nurix Therapeutics Presents New Positive Data from Phase - GlobeNewswire
Charles Schwab Investment Management Inc. Sells 111,684 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Shares Up 8.3%Here's What Happened - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Now Covered by BMO Capital Markets - MarketBeat
Polar Asset Management Partners Inc. Purchases Shares of 27,000 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Decoding 9 Analyst Evaluations For Nurix Therapeutics - Inkl
Where are the Opportunities in (NRIX) - Stock Traders Daily
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Redmile Group LLC - MarketBeat
Why Is Nurix Therapeutics, Inc. (NRIX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Insider Monkey
10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds - Insider Monkey
Patient Square Capital LP Makes New Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Parkman Healthcare Partners LLC Decreases Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Cinctive Capital Management LP Buys Shares of 105,228 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics chief legal officer sells $125,155 in stock By Investing.com - Investing.com Canada
Nurix Therapeutics chief legal officer sells $125,155 in stock - Investing.com
Nurix Therapeutics Announces Webcast To Review New Data - GlobeNewswire
Nurix Therapeutics Announces Webcast to Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented At the American Society of Hematology Annual Meeting - Marketscreener.com
Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting - The Manila Times
Fred Alger Management LLC Increases Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Wasatch Advisors LP Has $15.92 Million Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
23,578 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Purchased by Dynamic Technology Lab Private Ltd - MarketBeat
Vestal Point Capital LP Sells 75,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Massachusetts Financial Services Co. MA Sells 28,756 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics CEO to Present at Piper Sandler Healthcare Conference | NRIX Stock News - StockTitan
Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
(NRIX) Proactive Strategies - Stock Traders Daily
GSA Capital Partners LLP Sells 15,134 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Nurix gains EMA prime status for leukemia drug candidate - Investing.com India
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):